Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1124.02
GLPGF's Cash to Debt is ranked higher than
55% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. GLPGF: 1124.02 )
Ranked among companies with meaningful Cash to Debt only.
GLPGF' s 10-Year Cash to Debt Range
Min: 2.96  Med: 32.45 Max: No Debt
Current: 1124.02
Equity to Asset 0.76
GLPGF's Equity to Asset is ranked higher than
60% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GLPGF: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
GLPGF' s 10-Year Equity to Asset Range
Min: 0.5  Med: 0.71 Max: 0.77
Current: 0.76
0.5
0.77
F-Score: 5
Z-Score: 19.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -92.21
GLPGF's Operating margin (%) is ranked lower than
53% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. GLPGF: -92.21 )
Ranked among companies with meaningful Operating margin (%) only.
GLPGF' s 10-Year Operating margin (%) Range
Min: -59.16  Med: -33.12 Max: 1.78
Current: -92.21
-59.16
1.78
Net-margin (%) -92.82
GLPGF's Net-margin (%) is ranked lower than
54% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. GLPGF: -92.82 )
Ranked among companies with meaningful Net-margin (%) only.
GLPGF' s 10-Year Net-margin (%) Range
Min: -58.19  Med: -18.95 Max: 47.88
Current: -92.82
-58.19
47.88
ROE (%) -19.50
GLPGF's ROE (%) is ranked higher than
59% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. GLPGF: -19.50 )
Ranked among companies with meaningful ROE (%) only.
GLPGF' s 10-Year ROE (%) Range
Min: -24.8  Med: -9.47 Max: 17.79
Current: -19.5
-24.8
17.79
ROA (%) -16.03
GLPGF's ROA (%) is ranked higher than
60% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. GLPGF: -16.03 )
Ranked among companies with meaningful ROA (%) only.
GLPGF' s 10-Year ROA (%) Range
Min: -18.65  Med: -6.10 Max: 11.91
Current: -16.03
-18.65
11.91
ROC (Joel Greenblatt) (%) -528.85
GLPGF's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. GLPGF: -528.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLPGF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -247.33  Med: -58.01 Max: 9.71
Current: -528.85
-247.33
9.71
Revenue Growth (3Y)(%) -14.10
GLPGF's Revenue Growth (3Y)(%) is ranked lower than
64% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. GLPGF: -14.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GLPGF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -14.1  Med: 11.30 Max: 42.3
Current: -14.1
-14.1
42.3
EBITDA Growth (3Y)(%) 11.70
GLPGF's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. GLPGF: 11.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GLPGF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.6  Med: 11.70 Max: 39.5
Current: 11.7
-20.6
39.5
EPS Growth (3Y)(%) 2.80
GLPGF's EPS Growth (3Y)(%) is ranked higher than
61% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. GLPGF: 2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GLPGF' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.5  Med: 10.50 Max: 168.4
Current: 2.8
-69.5
168.4
» GLPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 49.10
GLPGF's P/E(ttm) is ranked lower than
62% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. GLPGF: 49.10 )
Ranked among companies with meaningful P/E(ttm) only.
GLPGF' s 10-Year P/E(ttm) Range
Min: 12.55  Med: 28.27 Max: 49.85
Current: 49.1
12.55
49.85
P/B 4.74
GLPGF's P/B is ranked lower than
56% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. GLPGF: 4.74 )
Ranked among companies with meaningful P/B only.
GLPGF' s 10-Year P/B Range
Min: 0.61  Med: 1.42 Max: 8.06
Current: 4.74
0.61
8.06
P/S 23.49
GLPGF's P/S is ranked lower than
69% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. GLPGF: 23.49 )
Ranked among companies with meaningful P/S only.
GLPGF' s 10-Year P/S Range
Min: 0.87  Med: 3.63 Max: 23.84
Current: 23.49
0.87
23.84
Current Ratio 3.54
GLPGF's Current Ratio is ranked lower than
56% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. GLPGF: 3.54 )
Ranked among companies with meaningful Current Ratio only.
GLPGF' s 10-Year Current Ratio Range
Min: 1.22  Med: 2.60 Max: 3.54
Current: 3.54
1.22
3.54
Quick Ratio 3.53
GLPGF's Quick Ratio is ranked lower than
53% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. GLPGF: 3.53 )
Ranked among companies with meaningful Quick Ratio only.
GLPGF' s 10-Year Quick Ratio Range
Min: 1.22  Med: 2.37 Max: 3.53
Current: 3.53
1.22
3.53
Days Sales Outstanding 70.34
GLPGF's Days Sales Outstanding is ranked lower than
56% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. GLPGF: 70.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLPGF' s 10-Year Days Sales Outstanding Range
Min: 55.58  Med: 79.08 Max: 114.23
Current: 70.34
55.58
114.23

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.29
GLPGF's Price/Net Cash is ranked lower than
69% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. GLPGF: 13.29 )
Ranked among companies with meaningful Price/Net Cash only.
GLPGF' s 10-Year Price/Net Cash Range
Min: 3.81  Med: 10.37 Max: 16.93
Current: 13.29
3.81
16.93
Price/Net Current Asset Value 10.95
GLPGF's Price/Net Current Asset Value is ranked lower than
64% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. GLPGF: 10.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GLPGF' s 10-Year Price/Net Current Asset Value Range
Min: 3.14  Med: 3.37 Max: 9.09
Current: 10.95
3.14
9.09
Price/Tangible Book 4.76
GLPGF's Price/Tangible Book is ranked higher than
54% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. GLPGF: 4.76 )
Ranked among companies with meaningful Price/Tangible Book only.
GLPGF' s 10-Year Price/Tangible Book Range
Min: 1.83  Med: 2.30 Max: 3.53
Current: 4.76
1.83
3.53
Price/Projected FCF 28.60
GLPGF's Price/Projected FCF is ranked lower than
85% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GLPGF: 28.60 )
Ranked among companies with meaningful Price/Projected FCF only.
GLPGF' s 10-Year Price/Projected FCF Range
Min: 8.2  Med: 8.20 Max: 8.2
Current: 28.6
Price/Median PS Value 6.49
GLPGF's Price/Median PS Value is ranked lower than
94% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. GLPGF: 6.49 )
Ranked among companies with meaningful Price/Median PS Value only.
GLPGF' s 10-Year Price/Median PS Value Range
Min: 0.3  Med: 1.06 Max: 2
Current: 6.49
0.3
2
Price/Graham Number 4.19
GLPGF's Price/Graham Number is ranked lower than
62% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. GLPGF: 4.19 )
Ranked among companies with meaningful Price/Graham Number only.
GLPGF' s 10-Year Price/Graham Number Range
Min: 1.2  Med: 1.20 Max: 1.2
Current: 4.19
Earnings Yield (Greenblatt) (%) -1.90
GLPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. GLPGF: -1.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLPGF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.7  Med: 0.80 Max: 1.3
Current: -1.9
-2.7
1.3

Analyst Estimate

Dec15
Revenue(Mil) 221
EPS($) -0.34
EPS without NRI($) -0.34

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0JXZ.UK, GLPG.Netherlands, GXE.Germany, GLPG.Belgium, GXEA.Germany, GLPG.USA,
Galapagos NV was founded in 1999. It is an integrated drug discovery company with capabilities from target discovery to clinical proof of concept. The company operates in two business divisions, R&D and Services. It also offers contract research services in the areas of in vitro, biology, analytics, among others. R&D operations specialize in the discovery and development of small molecules. Service operations offer target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The Group's operations were located in Belgium, Croatia, France, Switzerland, The Netherlands and United Kingdom. The Group's R&D division is located in Belgium, Croatia, France and The Netherlands, with its service division operating in the remaining countries. Sales of goods consist of the sale of chemical compound libraries on a non-exclusive basis. The Group faces competition from contract research companies that may bring products and services to the market which are more competitive or affordable and which might hurt the position of the service operations.
» More Articles for GLPGF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK